Theravance Biopharma TBPH Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $105.9M+288% | -$56.42M-2.2% | -$55.19M-106% | $872.13M+537% | ||
| $1.63M-4.9% | $1.71M-14.5% | $2M-46.2% | $3.72M-22.6% | ||
| $18.48M-13.6% | $21.39M-15.7% | $25.37M-36.1% | $39.73M-36.0% | ||
| —— | -$11.54M+57.3% | -$27M+85.6% | -$186.99M+10.0% | ||
| -$105.87M— | —— | —— | $1.15B— | ||
| -$3.25M-30.1% | -$2.5M+98.7% | -$198.93M+73.8% | -$758.95M-906% | ||
| —— | —— | -$258.63M— | —— | ||
| $238.5M+2,110% | -$11.87M+59.8% | -$29.49M+84.3% | -$187.56M+11.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
